Why Kinderhook’s Enhabit acquisition could reset the home health and hospice playbook
Home care demand is rising, but margins remain tight. Enhabit’s Kinderhook exit tests whether private equity can unlock scale without care risk.
Home care demand is rising, but margins remain tight. Enhabit’s Kinderhook exit tests whether private equity can unlock scale without care risk.
Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.
Hospital demand is resilient, but ARDT sentiment remains cautious. Ardent Health now has to prove margins can follow access growth.